|Posted date||Sep 2, 2011|
|International application number||2010JP064857|
|International publication number||WO 2011025050|
|Date of international filing||Aug 25, 2010|
|Date of international publication||Mar 3, 2011|
|Abstract||Disclosed are: an apoptosis inducer which can induce the apoptosis of various types of cells including tumor cells conveniently; and others. The apoptosis inducer is characterized by comprising a peptide (a) or (b) as mentioned below, a derivative of the peptide, or a salt of the peptide or the derivative: (a) a peptide comprising the amino acid sequence represented by formula (I): C-X-D-X-X-X-X-Y-X-C-X-C; and (b) a peptide which comprises an amino acid sequence produced by deleting, substituting or adding one or several amino acid residues in the amino acid sequence represented by the above-mentioned formula (I) and which has an apoptosis-inducing activity.|
|Outline of related art and contending technology||
Apoptosis, and one of the forms of cell death, disruption of the nucleus within a cell refers to cell death. Up to now, as the molecular mechanisms of apoptosis in cancer cells death, calcium pathway, death signaling pathway, ceramide pathway, mitochondrial, 5 and p53 of the apoptotic pathway is induced in the path of the two known molecular mechanisms (for example, 'Hashimoto yoshiyuki, new apoptosis molecular medicine, sheep earth Inc., 4 年 2001, pages 10-58' reference). A substance which induces apoptosis are known and many, such as mitomycin and taxol in clinical medicine and the anti-cancer agent is used. These artificial other than, or on a living body such as TNF α FasL (Fas ligand) protein exists in the induction of apoptosis. These artificial, natural apoptosis-inducing substances, such as cancer cells which are harmful to humans can be lethal to cells. As described above, also the anti-cancer agent used in chemotherapy, gene therapy also FasL being advanced studies, and applying this principle. Chemotherapy with, side effects to healthy tissue obstructs a portion of the treatment, effect on the lesion with the expectation that only, a gene therapy using gene transfer into the lesion has been studied. However, actually in the gene-introduced cells will, typically, a portion of the cells and the lesion, the cells were subsequently introduced a gene killed condition, a therapeutically effective protein or the like is not produced more of cells, as a result, the effect of the partial gene therapy in many cases. Therefore, the remaining of the pathological cells, it is required to repeatedly for gene transfer. In addition, the first gene by the introduction of the gene is introduced into the cells which were not, not easily HBlOl and there, the treatment is hindered.
In such a situation, various tumor cells to the cell can be easily induced apoptosis in the development of apoptosis-inducing agents has been desired. The present invention is, in consideration of the above circumstances with an object, shown below, inducer of apoptosis, pharmaceutical composition for the treatment of cancer and the like system according to the invention. (1) (A) or (b) the following peptides, derivatives or salts thereof characterized in that, apoptosis-inducing agents. (a) The following formula (I): (X is any amino acid residues, is a cysteine represents C, D represents an aspartic acid, phenylalanine is F.) A peptide comprising the amino acid sequence. (b) Amino acid sequence represented by the above formula (I) or an amino acid sequence in the 1 deletion, substitution or addition of the amino acid sequence, and, a peptide having apoptosis-inducing activity. In the above- (1) inducing agent, the amino acid sequence shown in formula (I), for example, SEQ ID NO:2 or amino acid sequence shown in SEQ ID NO and 3. In addition, the peptides of (a), for example, shown in SEQ ID NO:5 or SEQ ID NO:7 and comprising an amino acid sequence. (2) In a cell of interest to the above-mentioned (1) cells or cell populations comprising the action of the inducing agent, apoptosis-inducing method. In the method of induction, wherein the step of, for example, the cells of interest or cell population and the step of contacting the inducing agent. (3) The (1) inducing agent, a pharmaceutical composition for the treatment of cancer.
|Scope of claims||
(In Japanese)請求の範囲 [請求項1]
|IPC(International Patent Classification)||
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
※ Please contact us by E-mail or facsimile if you have any interests on this patent.
Contact Information for " APOPTOSIS INDUCER "
- Nihon University Nihon University Business, Research and Intellectual Property Center
- URL: http://www.nubic.jp/english/index.html
- Address: 4-8-24, Kudan-minami, Chiyoda-ku, Tokyo, Japan , 102-8275
- Fax: 81-3-5275-8328